Skip to main content
ATEC logo

ATEC · Alphatec Holdings, Inc.

Track ATEC — free
$6.68 -0.22 (-3.19%) At close · Nov 20
Market Cap
$1.04B
Shares
155.14M
Volume · Nov 20 3.05M Avg daily vol (3M) 3.36M

Price & Indicators

 

Key stats

Close
$6.68
Fri 20 Nov
Open
$6.79
Fri 20 Nov
Average volume, 30 days
4.8M
shares a session
Short interest
14.3M
9.2% of shares · 2.7 days to cover
Day range
$6.63$7.00
Open $6.79 Close $6.68
52-week closing range
$6.68$22.68
Close $6.68 70.5% under the high
Short volume, last session
49%
Last earnings
Oct 29, 2026
Latest filing
10-Q · Oct 29
Price history
Jan 2020 to Nov 2026

Up next

Feb 23, 2027 Est · unconfirmed · in 13 wks

Latest documents

2026
Oct 29
Earnings call
Lowers 2026 revenue outlook to $862 million on biologics, volumes

Alphatec lowered its full-year 2026 revenue expectation to approximately $862 million, growth of roughly 13%, including surgical revenue of approximately $789 million and EOS revenue of approximately $73 million. The company now expects adjusted EBITDA of approximately $137 million, a 16% margin, and free cash flow of $10 million, citing lower biologics attachment rates and procedure volumes.

Read from the first part of this long document
5 source passages
we are lowering our full year 2026 total company revenue expectations to approximately $862 million, representing growth of roughly 13% for the year We now expect surgical revenue of approximately $789 million, representing growth of approximately 15%, and EOS revenue of approximately $73 million. For the full year, 2026, we now expect adjusted EBITDA margins of 16% or approximately $137 million We now expect free cash flow of $10 million for the full year This update reflects the lower biologics attachment rate, lower overall procedure volumes due to current market trends Open the document at this passage
Oct 29
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Revenue up 13% in quarter; litigation expenses down 91%

Revenue from products and services increased $24.7 million, or 13%, for the three months ended September 30, 2026, and $75.6 million, or 14%, for the nine months, from higher product volume. Litigation-related expenses decreased $5.9 million, or 91%, mainly due to a litigation settlement in the prior-year nine months. Cash and cash equivalents were $79.9 million at September 30, 2026, down from $160.8 million at December 31, 2025.

Revenue $221.17M ▲ 12.6% Net loss $5.47M Diluted EPS -$0.03
Read from the MD&A section
5 source passages
Revenue from products and services increased $24.7 million, or 13%, and $75.6 million, or 14%, for the three and nine months ended September 30, 2026, respectively, compared to the same periods in 2025. The increase was primarily due to an increase in product volume that was due to the increase in our surgeon user base, continued expansion of our new product portfolio, and increasing adoption of our technology. Litigation-related expenses decreased $5.9 million, or 91%, and $19.3 million, or 95%, for the three and nine months ended September 30, 2026, respectively, compared to the same periods in 2025. The decrease was primarily related to a litigation settlement during the nine months ended September 30, 2025. Cash and cash equivalents were $79.9 million and $160.8 million at September 30, 2026, and December 31, 2025, respectively. Open the document at this passage
Oct 29
Current report 8-K
Revenue rises 13% with $38 million adjusted EBITDA

Alphatec Holdings, Inc. reported $221 million revenue for September 30, 2026, up 13% year-over-year, and $38 million adjusted EBITDA. For fiscal year 2026, it expects approximately $862 million revenue and approximately $137 million adjusted EBITDA.

Financial results
5 source passages
Alphatec Holdings, Inc. (Nasdaq: ATEC), a spine-focused provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, today announced financial results for the quarter ended September 30, 2026, and business highlights. Total revenue of $221 million, up 13% year-over-year Adjusted EBITDA of $38 million For fiscal year 2026, the Company now expects total revenue of approximately $862 million The Company now expects adjusted EBITDA of approximately $137 million Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$839.72M
Trailing 12 months
Net income (TTM)
−$86.89M
Trailing 12 months
Revenue growth YoY
+12.6%
Year over year
Operating margin
-3.6%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
0.3%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
−$467.06M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+3.9%
Year over year · more shares
Price change (1Y)
-65.9%
Trailing year
Short interest
9.2%
Latest settlement · 2.7 days to cover
View all 125 metrics

AI Brief

Q2 FY26 earnings call · Aug 4, 2026
Q2 FY26

TL;DR. ATEC delivered Q2 revenue of $214M (up 15%) with surgical revenue up 17% on 20% case volume growth, raised full-year adjusted EBITDA guidance to ~$140M from ~$134M, while reaffirming revenue (~$882M) and free cash flow (≥$20M) outlook; revenue per case guidance moved from flattish to down low single digits as biologics attach rate only stabilized.

Bullish
  • + Q2 surgical revenue grew 17% to $196M on 20% case volume growth and 24% net new surgeon user growth.
  • + Raised full-year 2026 adjusted EBITDA guidance to ~$140M from prior ~$134M.
  • + Gross margin expanded 260 bps year-over-year to 72.5%, with operating expenses improving ~260 bps as a percentage of revenue.
  • + Refinancing extends maturities to 2031 and is expected to reduce annual interest expense by more than $6M.
  • + EOS Insight adoption driving ~32% implant revenue lift per surgeon within six months of Go-Live.
Bearish
  • − Full-year revenue per case guidance lowered from flattish to down low single digits as biologics attach only stabilized rather than improved.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Strong Sell Momentum Very Weak Sentiment Neutral Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 35.9 · fear Equity put/call 0.77
Technical
price trend
Strong Sell
50 / 200-day cross No cross
Price vs 200-day avg −33%
below
Price vs 50-day avg −30%
below
RSI (14) 33
neutral
MACD trend Negative
52-week position 0%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −40%
trailing
6-month return −11%
trailing
YTD return −68%
this year
Relative strength −2%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $9 › 200d $10 — 200d above 50d
Institutional flow Accumulating
+4% holders QoQ · +45 funds added
Insider flow Accumulating
Net +$1.4M over 90 days · 0% sells
Short interest Rising
9.19% of shares out · ▲ +7.3% MoM · 2.7 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
279 holders — mid 3-yr range
Squeeze score 51
elevated · 0–100
Fundamentals
Strong
Revenue growth −15%
Y/Y
Gross margin 523%
expanding
EPS growth +15%
Y/Y
Free cash flow $2.8M
Buyback $25.0M
authorized
Balance sheet $405.1M
net debt
Quant / Vol
risk profile
Very High
Volatility 79%
annualized · 1-yr
Max drawdown −71%
past year
ATR 8.3%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 5 of last 5
Latest guidance · from the 8-K filed Oct 29, 2026
Total revenue · fiscal year 2026 Lowered $862M
Aug 4, 2026 $882M changed to Oct 29, 2026 $862M
prior FY $764.16M midpoint +12.8% Y/Y
Surgical revenue · fiscal year 2026 Lowered $789M
Aug 4, 2026 $805M changed to Oct 29, 2026 $789M
Total revenue growth · fiscal year 2026 13%
EOS revenue · fiscal year 2026 Lowered $73M
Aug 4, 2026 $77M changed to Oct 29, 2026 $73M
Adjusted EBITDA · fiscal year 2026 Non-GAAP Lowered $137M
Aug 4, 2026 $140M changed to Oct 29, 2026 $137M
Surgical revenue growth · fiscal year 2026 15%
Free cash flow · fiscal year 2026 $10M
Previous outlook earlier release · from the Earnings Call filed Aug 4, 2026

Still-open targets the latest release did not restate under the same label.

Free cash flow · full year at least $20M
Gross margin · second half 71%
Prior guidance period ended · from the Earnings Call filed Aug 4, 2026
Free cash flow · third quarter $4M – $6M
Guided vs delivered · last 5 settled
Total revenue fiscal year ending December 31, 2025
guided $760M
$764.16M Beat +0.5%
Total revenue fiscal year ended December 31, 2024
guided $602M
$611.56M Beat +1.6%
Total revenue fiscal year ended December 31, 2023
guided $472M
$482.26M Beat +2.2%
Total revenue fiscal year ended December 31, 2022
guided $340M
$350.87M Beat +3.2%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Strong Sell
4 · 3 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−33% Bearish
Price vs 50-day avg
−30% Bearish
RSI (14)
33 Neutral
MACD trend
Negative Bearish
52-week position
0% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $9 › 200d $10 — 200d above 50d
Institutional flow Accumulating
+4% holders QoQ · +45 funds added
Insider flow Accumulating
Net +$1.4M over 90 days · 0% sells
Short interest Rising
9.19% of shares out · ▲ +7.3% MoM · 2.7 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
279 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $7 Now $7 · 0% Range high $23
vs 200-day avg -33% vs 50-day avg -30%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Adjusted EBITDA non-GAAP $56.69M six months ended June 30, 2026 —
Adjusted EBITDA margin non-GAAP 14% six months ended June 30, 2026 —
Adjusted EBITDA margin expansion non-GAAP 420 the second quarter —
Case volume growth 20% the second quarter —
Net new surgeon users growth 24% the second quarter —
Non-GAAP gross margin non-GAAP 72.5% Quarter Ended June 30, 2026 —
Non-GAAP gross profit non-GAAP $154.72M three months ended June 30, 2026 —
GAAP → non-GAAP reconciliation
GAAP Gross profit, GAAP 154.1M
+65K amortization of acquired intangible assets
+559K stock-based compensation
= Non-GAAP gross profit 154.72M
Non-GAAP net income non-GAAP $11.73M six months ended June 30, 2026 —
Non-GAAP net income per share non-GAAP $0.07 three months ended June 30, 2026 —
Non-GAAP operating expenses non-GAAP $135M Quarter Ended June 30, 2026 —
GAAP → non-GAAP reconciliation
GAAP Operating expenses, GAAP 156.01M
-17.59M Stock-based compensation
+86K Litigation-related expenses
-3.92M Amortization of acquired intangible assets
+0K Restructuring expenses
= Non-GAAP operating expenses 134.59M
Surgical revenue $196M Quarter Ended June 30, 2026 —
Surgical revenue growth 17% the second quarter —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Medical Devices — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
ATEC
Alphatec Holdings, Inc.
this stock
$1.04B -68.3% -15.4% — 9.2%
ABT
Abbott Laboratories
$178.39B -17.8% +5.7% 38.4 1.1%
MDT
Medtronic plc
$127.84B +4.0% +8.4% 24.6 1.8%
SYK
Stryker Corp
$118.01B -11.8% +11.2% 33.0 1.7%
BSX
Boston Scientific Corp
$60.85B -56.0% +12.5% 17.8 2.4%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
279
% held
74.2%
Net QoQ
+3.4M sh
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
197
View
Short & Settlement
Short Interest Rising
Shares short
14.3M
Days to cover
2.7d
Change
+967.7K sh
View
Short Volume
Short vol %
49%
As of
Nov 20, 2026
Short Total
View
Fails to Deliver
FTD shares
551
Value
$6.2K
As of
Oct 13, 2026
View
Off-Exchange
Off-exchange %
42.4%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Insider Trades Cluster buy
Net (90d)
+$1.4M
Buyers / Sellers
3 / 0
Buyers Sellers
View
Financials
Financials
Revenue (FY)
$101.7M
Net income (FY)
$-143.4M
EPS diluted
$-0.96
View
Buybacks
Authorized
$25.0M
View
Filings
SEC Filings
Latest
10-Q
Filed
Oct 29, 2026
This year
17

Revenue from products and services increased $24.7 million, or 13%, for the three months ended September 30, 2026, and $75.6 million, or 14%, for the nine months, from higher product volume. Litigation-related expenses decreased $5.9 million, or 91%, mainly due to a litigation settlement in the prior-year nine months. Cash and cash equivalents were $79.9 million at September 30, 2026, down from $160.8 million at December 31, 2025.

View
Proposed Sales
Value
$84.5K
Shares
8.2K
Filed
Aug 5, 2026
View
Exempt Offerings
Offering
$168.0M
Filed
Dec 31, 2020
View
Earnings & Events
Webcasts Upcoming
Next webcast
Dec 1, 2026
Last webcast
Oct 29, 2026
View
Investor Relations
Latest news
ATEC Announces Participation in U…
Published
Nov 11, 2026
Upcoming events
3
View

Performance

5D 20D 120D MTD YTD
ATEC -5.5% -39.9% -10.7% -5.1% -68.3%
SPY -8.6% -9.2% -9.2% -8.7% +1.2%
vs SPY +3.0% -30.6% -1.5% +3.6% -69.4%

Capital returns

Buyback program · as of Aug 3, 2021
Authorized
$25.00M
Spent (derived)
—
Remaining
—

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1350653 CUSIP 02081G201 13F (30d) 257 filings 239 filers Visit website Investor relations